Rheumatoid Arthritis - MorphoSys Announces Completion Of First Dosing In Phase 1 Trial For MOR103 Program
May 15th 2008Drug InformationArthritis
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced the completion of a first dosing regimen in a phase 1 clinical study on healthy volunteers of the HuCAL-derived antibody MOR103 with no adverse events reported. Six healthy volunteers in the first dosing group have been enrolled and received MOR103 injections, three volunteers received placebo. The safety review of the medical data from the lowest dosing group concluded that it was safe to proceed to the second dosing group.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
